Completed PHASE1 INTERVENTIONAL NCT00433485

Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants

In Vivo and In Vitro Pharmacology of Sirolimus in Subjects With Basal Cell Nevus Syndrome

Sponsor: National Cancer Institute (NCI)

Conditions Neoplastic Syndrome Non-melanomatous Skin Cancer

Interventions biopsy comparative genomic hybridization gene expression analysis laboratory biomarker analysis mass spectrometry microarray analysis protein expression analysis proteomic profiling sirolimus

Updated 5 times since 2017 Last updated: Sep 21, 2016 Primary completion: Mar 31, 2008 Completion: Mar 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Neoplastic Syndrome and Non-melanomatous Skin Cancer and is currently completed. National Cancer Institute (NCI) leads this study, which shows 5 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Yale University

Data source: Yale University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.